NR2F6 promotes the malignant progression of neuroblastoma as an indicator of poor prognosis

Background NR2F6 is an orphan nuclear receptor with dual tumorigenic activity in the immune system and tumor cells, playing an essential role in tumor differentiation and immunity. This study aimed to investigate the expression level of NR2F6 in various tumors and its effect on neuroblastoma (NB). Methods We evaluated the role of NR2F6 in the genesis and development of 34 different tumors through multiple databases. In addition, we investigated the effects of NR2F6 expression levels on NB risk factors and prognosis using pathology sections and clinical data from primary retroperitoneal NB in children. The effects on cell proliferation, invasion, and migration were explored by knocking down NR2F6 expression in SK-N-BE(2) and SK-N-SH cells. Results The findings showed that NR2F6 was significantly correlated with the prognosis of NB and was an important indicator suggesting disease regression. In addition, NR2F6 knockdown slowed down NB cells’ proliferation, invasion, and migration ability in vitro. Conclusion Our results suggest that NR2F6 plays a crucial role in tumor-promoting effects and can be used as a potential prognostic marker for NB.

• Publication year

  2025

• Venue

  PLoS ONE

• Publication date

  2025-05-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1371/journal.pone.0324334PMID 40424451PMCID 12112146
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dual roles of HK3 in regulating the network between tumor cells and tumor-associated macrophages in neuroblastoma

  2024cited by this paper
• BI-D1870 Induces Mitotic Dysfunction and Apoptosis in Neuroblastoma by Regulating the PI3K-Akt-mTORC1 Signal Axis

  2023cited by this paper
• Human Mesenchymal Stem Cells-Derived Exosome Mimetic Vesicles Regulation of the MAPK Pathway and ROS Levels Inhibits Glucocorticoid-Induced Apoptosis in Osteoblasts

  2023cited by this paper
• MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas

  2023cited by this paper
• Dual role of ARPC1B in regulating the network between tumor-associated macrophages and tumor cells in glioblastoma

  2022cited by this paper
• Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma

  2022cited by this paper
• The expression and biological effect of NR2F6 in non-small cell lung cancer

  2022cited by this paper
• Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6

  2021cited by this paper
• MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

  2021cited by this paper
• Cancer and stem cells

  2021cited by this paper
• Comprehensive mapping of the human cytokine gene regulatory network

  2020cited by this paper
• The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

  2020cited by this paper
• Regulation of docetaxel chemosensitivity by NR2F6 in breast cancer.

  2020cited by this paper
• The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis

  2019cited by this paper
• Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression

  2019cited by this paper
• Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway

  2019cited by this paper
• The landscape of genomic alterations across childhood cancers

  2018cited by this paper
• The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo

  2018cited by this paper
• The Immune Landscape of Cancer.

  2018cited by this paper
• Neuroblastoma: clinical and biological approach to risk stratification and treatment

  2018cited by this paper
• Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade

  2018cited by this paper
• An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

  2018cited by this paper
• Advances in emerging drugs for the treatment of neuroblastoma

  2017cited by this paper
• TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.

  2017cited by this paper
• NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer

  2016cited by this paper
• Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.

  2016cited by this paper
• Molecular and cellular insights into T cell exhaustion

  2015cited by this paper
• The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance

  2015cited by this paper
• Robust enumeration of cell subsets from tissue expression profiles

  2015cited by this paper
• Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

  2014cited by this paper
• Relevance of the MEK/ERK Signaling Pathway in the Metabolism of Activated Macrophages: A Metabolomic Approach

  2012cited by this paper
• Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.

  2011cited by this paper
• The orphan nuclear receptor EAR2 is overexpressed in colorectal cancer and it regulates survivability of colon cancer cells.

  2011cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• Neuroblastoma

  2007cited by this paper
• Immunogenicity of Human Neuroblastoma

  2004cited by this paper
• Cox's regression model for counting processes: a large sample study : (preprint)

  1982cited by this paper

• No citing papers are available for this paper.